Um dos principais objetivos do Life4me+ - é prevenir novos casos de HIV e outras ISTs, hepatite C e tuberculose.

O aplicativo ajuda a estabelecer uma comunicação anônima entre médicos e pessoas soropositivas. A App permite que você organize convenientemente o seu horário de toma dos medicamentos e defina de uma forma personalizada os lembretes.

Todas as notícias / Outubro 2018

Arquivo

✕

19 outubro 2018

7745

Gilead and Aelix join forces to develop a promising anti-HIV combination

Gilead and Aelix join forces to develop a promising anti-HIV combination

American pharmaceutical company Gilead Sciences - the world leader in the development of drugs for the treatment of HIV and hepatitis C - has teamed up with the Spanish Aelix Therapeutics in order to develop a fundamentally new ART-regimen, according to PMLive.

18 outubro 2018

7925

IDWeek-2018 presented new data confirming the long-term effectiveness of ART-schemes “in one pill”

IDWeek-2018 presented new data confirming the long-term effectiveness of ART-schemes “in one pill”

According to a number of studies presented at the IDWeek-2018 conference in San Francisco, several newest ART-schemes “in one pill” are capable of supporting an undetectable burden of HIV for two years or more.

17 outubro 2018

6620

Spanish scientists told about promising results of HIV suppression in stem cell transplantation

Spanish scientists told about promising results of HIV suppression in stem cell transplantation

A group of researchers from the Madrid Hospital. Gregorio Maranyon and the IrsiCaixa HIV Research Institute of Barcelona last Tuesday reported on the impressive results of suppressing HIV-positive patients with virus strains in hidden reservoirs thanks to the stem cell transplant ...

15 outubro 2018

6092

American patients admitted that they are not ready to switch to new ways of ART delivery

American patients admitted that they are not ready to switch to new ways of ART delivery

According to a US study published in Open Forum Infectious Diseases, two-thirds of people taking combined antiretroviral therapy (ART) will be interested in switching to the oral regimen once a week. The idea of switching to long-term injection therapy is supported by less ...